Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, provides an overview of the latest trial updates presented at ASH 2020 for several B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma. He also discusses the promise of off-the-shelf allogeneic CAR T-cell therapies but considers the potential obstacles related to this treatment modality. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020
Теги
Speaker: Saad UsmaniInstitution: Levine Cancer InstituteEvent: VJVirtualEvent: ASH 2020Format: InterviewSubject: Multiple MyelomaField: CAR-T & Cellular TherapyField: Immuno-OncologyField: PerspectivesField: TreatmentField: Trial UpdatesMedicines: Idecabtagene vicleucelMedicines: ciltacabtagene autoleucelMedicines: Orvacabtagene autoleucelMedicines: CT053Allo-CAR-TCAR-T constructB-cell maturation antigen
![[ Who Is Taller? ] Educational Song for Kids | BIG SHOW #3-3 ★BIGBOX](http://i.ytimg.com/vi/BS1AkAHAYdk/mqdefault.jpg)
![No electric cars: Ox-wagons instead. MADAGASCAR 🇲🇬[S7-E94]](https://i.ytimg.com/vi/UrNEjcXqZqk/mqdefault.jpg)
